Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 18, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and Ordinary Share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of equity interest changes and does not contain financial performance data.
Material Changes
The filing details the following specific changes in equity interests:
- Employee Share Option Plan: On May 17, 2005, the GlaxoSmithKline Employee Trust transferred 10,820 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan (Notional Investment): Following a re-valuation on May 12, 2005, at a price of $49.95 per share, there was an increase in the notional allocation of Ordinary Share ADRs for specific directors:
- Dr. J-P Garnier: 46 shares
- Dr. T Yamada: 16 shares
- US Retirement Savings Plan (Fund Movement): On May 12, 2005, the total number of Ordinary Share ADRs held by the fund changed from 18,168,570 to 18,264,444 at an average price of $50.67.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on regulatory disclosure of director shareholdings.
Key Facts for Investor Verification
- Verify the impact of the 10,820 share transfer from the GSK Trust on the company's outstanding share count.
- Confirm the current total holdings of the US Retirement Savings Plan (18,264,444 ADRs) and its valuation basis.
- Note that Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop hold indirect interests through the GSK Trust and/or the US Retirement Savings Plan as potential beneficiaries.